Study Details
A study of the safety and tolerability of ASP7317 in adults who are losing their clear, sharp central vision due to geographic atrophy secondary to dry age-related macular degeneration
Clinicaltrials.gov ID
Astellas Study ID
7317-CL-0003
EudraCT ID
N/A
Condition
Age-related Vision Loss
Phase
Phase 1
Age
50 years - N/A
Sex
Female & Male
Product
ASP7317
Type
Interventional
Trial Dates
Jul 2018 - Aug 2024
Masking
None (Open Label)
Enrollment number
18
A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of ASP7317 for Geographic Atrophy Secondary to Age-related Macular Degeneration
Study summary
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A study of the safety and tolerability of ASP7317 in adults who are losing their clear, sharp central vision due to geographic atrophy secondary to dry age-related macular degeneration? Contact us by filling our your information to the right and we’ll respond to you.
Locations
NJ Retina
New Brunswick, United States, 08901
Retina Consultants of Southwest Florida & National Ophthalmic Research Institute
Fort Myers, United States, 33912
University of Washington
Seattle, United States, 98104
Tennessee Retina, PC
Nashville, United States, 37203
Mid-Atlantic Retina
Philadelphia, United States, 19107
Retina Specialty Institute
Pensacola, United States, 35203
Mass Eye and Ear Infirmary Ophthalmology Clinical Research Office
Boston, United States, 02114
Jules Stein Eye Institute
Los Angeles, United States, 90095
Valley Retina Institute
McAllen, United States, 78503
Retinal Consultants of Arizona LTD, Retinal Research Institute
Phoenix, United States, 85053
Emory University Eye Center
Atlanta, United States, 30322
Stanford University Byers Eye Institute
Palo Alto, United States, 94303